| Code | CSB-RA326953MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to itolizumab, targeting the CD6 glycoprotein expressed on mature T lymphocytes and a subset of B cells. CD6 functions as a co-stimulatory receptor that modulates T cell activation and proliferation through interactions with its ligand ALCAM (activated leukocyte cell adhesion molecule). This receptor plays a critical role in regulating immune responses and maintaining the balance between T cell activation and tolerance. Dysregulated CD6 signaling has been implicated in various autoimmune and inflammatory conditions, including psoriasis, rheumatoid arthritis, and multiple sclerosis.
Itolizumab, the reference antibody, is a humanized IgG1 monoclonal antibody that binds to domain 1 of CD6, inhibiting the CD6-ALCAM interaction without depleting T cells. It has been clinically developed for treating autoimmune disorders and has shown efficacy in moderate-to-severe plaque psoriasis. This biosimilar antibody serves as a valuable research tool for investigating CD6-mediated immune regulation, studying T cell-dependent inflammatory mechanisms, and exploring potential therapeutic interventions in autoimmune diseases.
There are currently no reviews for this product.